SCHEMBL10330656

SCHEMBL10330656

COC(=O)c1cccc(NC(=O)c2cc3ccc(C)cc3[nH]c2=O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR17 Q13304 1/20 0.54
▸ DYRK1A Q13627 1/20 0.53
▸ DYRK1B Q9Y463 1/20 0.53
▸ RAB9A P51151 5/20 0.52
▸ ALDH1A1 P00352 4/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ TP53 P04637 1/20 0.48
▸ ABL1 P00519 1/20 0.47
▸ RIN1 Q13671 1/20 0.47
▸ HPGD P15428 2/20 0.47
▸ NR4A1 P22736 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ KCNK3 O14649 1/20 0.47
▸ KCNK9 Q9NPC2 1/20 0.47
▸ HTT P42858 1/20 0.46
▸ MEN1 O00255 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10330651 0.89 NR1H4 (0.53) RAB9AALDH1A1SMN1; SMN2TP53HTT
SCHEMBL10321615 0.83 RAB9A (0.50) GPR17DYRK1ADYRK1BRAB9AALDH1A1
SCHEMBL10330638 0.80 KDM4E (0.61) ALDH1A1KDM4ETSHRHSD17B10SMN1; SMN2
SCHEMBL11333469 0.78 DYRK1A (0.60) DYRK1ADYRK1BRAB9AALDH1A1KDM4E
SCHEMBL21639501 0.77 RAB9A (0.51) GPR17DYRK1ADYRK1BRAB9AALDH1A1
SCHEMBL14363287 0.77 GPR17 (0.63) GPR17RAB9AALDH1A1SMN1; SMN2TP53
SCHEMBL21639567 0.76 EGFR (0.54) DYRK1ADYRK1BRAB9AALDH1A1KDM4E
SCHEMBL10322342 0.76 POLB (0.47) DYRK1ADYRK1BRAB9AALDH1A1TSHR
SCHEMBL10446504 0.74 DYRK1A (0.53) DYRK1ADYRK1BRAB9AALDH1A1TSHR
SCHEMBL10322470 0.74 RAB9A (0.43) DYRK1ADYRK1BRAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES PSEN1, BRCA1, PSEN2 GPR17 4039/4885DYRK1A 1366/4885DYRK1B 2109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback